Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
aDC1 Dendritic Cell Vaccine for HIV
NCT05786937Phase 1Unknown
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Jun 2023
- Primary completion
- Dec 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised trial of alpha-type-1-polarized dendritic cell vaccine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Primary endpoints: Adverse events related to the study product at 6 months, Plasma viral load setpoint after the intervention at 6 months and 1 more. Status: unknown.
02
Drugs
alpha-type-1-polarized dendritic cell vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05786937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05786937.